CISPLATIN CISPLATIN KEMOPLAT KEMOPLAT UNISTIN UNISTIN ONCOPLATIN CISPLATIN PLATINIL CEPLATIN CEPLATIN CEPLATIN CISPLASOL CISPLASOL PLATIMIT CISPLANTINO GADOR CISPLANTINO GADOR BLASTOLEM BLASTOLEM PLATIDIAM PLATOSIN PLATOSIN CISPLATIN CISPLATIN CISPLATINUM CISPLATINUM CISPLATINUM CYTOPLATIN CYTOPLATIN

Dose: 50 to 120 mg/sq.meter
Single Dose: 85 (85)
Frequency: As recommended.
Route: IV
Instructions: Single dose, every month, As Required

Dose: 32 to 17.5 mg/sq.meter
Single Dose: 25 (24.75)
Frequency: 24 hourly
Route:
Instructions:

Cisplatin also known as Cisplatinum, Cisplatinum, Cisplatinum. . It is of Synthetic origin and belongs to Chloroplatinum. It belongs to Cross Linkage (DNA acting) pharmacological group on the basis of mechanism of action and also classified in Antineoplastic Agent, Alkylating Agent pharmacological group.The Molecular Weight of Cisplatin is 300.10. Its pKa is not relevant.

Cisplatin is contraindicated in conditions like Renal failure,Bone marrow depression,Peripheral neuropathy.

The severe or irreversible adverse effects of Cisplatin, which give rise to further complications include Neuropathy, Hypersensitivity reactions, Ototoxicity, Reduction in creatinine clearance, Elevation in serum creatinine, Vascular toxicity, Vascular toxicity.Cisplatin produces potentially life-threatening effects which include Bone marrow aplasia, Myelosuppression, Renal damage, Anaphylactic reactions, Depression. which are responsible for the discontinuation of Cisplatin therapy.The symptomatic adverse reactions produced by Cisplatin are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, Vomiting, Anorexia, Tinnitus, Azotemia.

Cisplatin is primarily indicated in conditions like Bladder carcinoma, Metastatic germ cell cancers (seminoma and teratoma), Metastatic ovarian carcinoma, Metastatic testicular cancer, Non-small cell lung carcinoma, Small cell lung cancer, Squamous cell carcinoma.

Cisplatin is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAmikacin (Sulphate)Amphotericin BBleomycinIncreased pulmonary toxicity when Bleomycin given with Cisplatin.Cisplatin reduces renal elimination of Bleomycin and increases drug toxicity.CapreomycinIncreased risk of nephrotoxicity and ototoxicity when capreomycin given with platinum compounds (e.g Cisplatin).CetuximabDiazoxideEtoposideFluorouracilFosphenytoinFrusemide or FurosemideFurosemide may enhance the ototoxic effect of Cisplatin.ModerateMonitor for evidence of ototoxicity during concomitant therapy with cisplatin and Furosemide.Gallium NitrateGemcitabineGentamicinHydralazine (HCl)Coadministration increases the risk of peripheral neuropathy.ModerateClosely monitor for the symptoms of neuropathy such as burning, tingling, pain, or numbness in hands and feet. Either reduce the dose or discontinue in patients who develop peripheral neuropathy.IfosfamideIfofasfamide may potentiate toxicity produced by cisplatin.ModerateSerial audiograms is advised.MannitolNetilmicin (Sulphate)PaclitaxelPodophyllumThe risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. In some cases, the neuropathy may progress or become irreversible despite discontinuation of the medications.ModerateCaution is advised during concomitant use of agents with neurotoxic effects. Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded.Propranolol (HCl)RituximabCisplatin because serious kidney toxicity or kidney failure may occur. TacrolimusTobramycin These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

No data has been reported.

Drug should not be given to Pregnant Mothers, patients suffering from Kidney dysfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Inj (reconstituted soln) Store at room temperature. Refrigeration and Freezing is not recommended. Protect from Sunlight. Use within 20 hrs if kept at room temperature.

Cisplatin should be used with caution in patients with pre-existing blood disorders, hearing abnormalities, kidney disease or any allergies. This medication must not be used during pregnancy or lactation.